Revenue grew 19.62% to ¥1.29 billion and net profit rose 2.22% to ¥197 million, driven by strong pharmaceutical and alloy segments. R&D investment reached ¥236 million, with no cash dividend as profits were reinvested. Key risks include reliance on pharma and market certification for alloys.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.